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Background: Liver disease is the second cause of death among HIV patients receiving highly active antiretroviral
therapy (HAART) in Europe. HIV patients have a high prevalence of chronic HBV (6–10%) and HCV (33%) co-infection
, and accelerated progression of viral hepatitis. Furthermore, the long duration of both HIV and HCV diseases in the
HAART era increases the risk of hepatocellular carcinoma.
Findings: We report the case of a 49 year -old HIV/HCV co-infected male patient who developed hepatocellular
carcinoma. The patient underwent a partial hepatectomy, and a few months later was treated with transcatheter
arterial chemoembolisation due to hepatocarcinoma recurrence. Two months later, advanced hepatocellular
carcinoma was diagnosed and sorafenib therapy was initiated. The patient achieved partial response of the main
lesions, complete regression of the smallest lesions and did not experience clinical progression during the 20-
month follow-up period. During therapy with sorafenib, the patient was treated with HAART with good viral and
immunological responses. We used the therapeutic drug monitoring to assess antiretroviral concentrations during
co-administration of sorafenib. Fosamprenavir Ctrough was found under the minimum level recommended by
international guidelines. No grade 3 or 4 toxicities were observed. At month 20 of treatment, new liver lesions with
portal vein thrombosis were diagnosed. After 28 months of sorafenib therapy, the patient deceased for severe liver
insufficiency.
Conclusions: Sorafenib monotherapy demonstrated a marked delay in HCC disease progression in an HIV/HCV co-
infected patient. Fosamprenavir Ctrough was found under the minimum level recommended by international
guidelines, suggesting a possible interaction.
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Introduction
People infected with HIV have a greater prevalence of
chronic HBV (6–10%) and HCV (33%) and accelerated pro-
gression of viral hepatitis than the general population [1].
Since the initiation of highly active antiretroviral therapy
(HAART) in 1996, the incidence of AIDS-related morbidity
and mortality has dramatically decreased, resulting in
increased life expectancy. However, the causes of death have
shifted from AIDS-defining to non -AIDS defining diseases* Correspondence: pasqualedenardo@libero.it
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reproduction in any medium, provided the orwith increased risk of end-stage liver diseases (ESLD) [2].
According to several studies, the complications of HCV and
HBV are the second most frequent cause of death after
AIDS in HIV- infected patients, accounting for around 10%
of deaths [2,3]. Two large, phase III trials demonstrated that
the orally active multikinase inhibitor sorafenib is effective
in leading to a longer median overall survival time, and time
to progression in patients with advanced hepatocellular car-
cinoma (HCC) [4,5]. Despite the clinical relevance of HCC
in HIV-HCV co-infection, there is little data regarding the
use of sorafenib for HCC in HIV/HCV co-infected patients.
Furthermore, data on a possible interaction between sorafe-
nib and antiretrovirals are rather scarce [6-8].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 49 year-old Italian male with HIV infection (known
since 1988), and CDC stage C3 for pulmonary tubercu-
losis, presented an HCV infection (genotype 4) since
1992. His HBV-DNA and hepatitis B surface antigens
were negative. He was on antiretroviral therapy since
1991 with good immune-virological control. In Decem-
ber 2005, a liver biopsy showed a moderate grade of
necroinflammatory activity and a moderate intensity of
fibrosis (Ishak grading 13, Ishak staging 3). HAART was
interrupted in March 2006, and in May 2006, he started
antiviral treatment with Peg-interferon 180 mcg/week
and ribavirin 1000 mg/day. Sixteen weeks later, antiviral
therapy was discontinued for virological failure (>
300.000 HCV-RNA UI/mL). In June 2007, 15 months
after HAART interruption, the patient started another
antiretroviral therapy with emtricitabine (FTC), tenofovir
(TDF), fosemprenavir (FPV) and ritonavir (RTV)
(100 mg daily): the Ctrough determination of FPV was
1176 ng/mL, far above the Ctrough levels suggested by
international guidelines (>400 ng/mL) [9]. In July 2007,
an abdomen computed tomography scan (TC) showed a
single nodule of 4 cm in the VI hepatic segment. A histo-
logical diagnosis of HCC was made and he underwent a
partial hepatectomy. In April 2008, a new liver lesion of
2.4 cm in the VII-VIII segment was detected and treated
with Transcatheter Arterial Chemoembolisation (TACE).
Three months later, an abdomen CT scan revealed a
right subdiaphragmatic fluid collection and a non-
homogenic solid nodular lesion on the resection margin
of the previous hepatectomy (Figure 1). Smaller lesions
were described in II, III and IV segments. His α-
fetoprotein was 20.43 IU/ml. In December 2008, the pa-
tient started treatment with sorafenib 800 mg/die, which
was reduced to 400 mg/day after 2 months due to a
grade II hand-foot skin adverse reaction. Child-PughFigure 1 Abdomen TC scan before starting sorafenib. Non-
homogenic solid nodular lesion on the resection margin of the
hepatectomy.cirrhosis score at the beginning of sorafenib treatment
was 6, grade A. The radiological controls during follow-
up, until month 20 of therapy showed complete regres-
sion of the described nodular lesion with no progression
of the smaller lesions (Figure 2). No appearance of new
relapses was observed. Fosamprenavir Ctrough was found
under the minimum level recommended by international
guidelines (Ctrough: 115 ng/mL; Cmax: 436 ng/mL).
Nevertheless, HIV-RNA was still undetectable. At month
20 of treatment, we found an increment of α-fetoprotein
up to 200 IU/ml, associated with new hepatic lesions and
occurrence of a complete portal vein thrombosis. Sorafe-
nib administration continued after the documented dis-
ease progression. In April 2011, after 28 months of
sorafenib therapy, the patient deceased for severe liver
insufficiency. A summary of CD4 cell count and HIV-
RNA values is showed in Table 1. Over the entire period
of treatment with sorafenib the patient had taken PI-
based HAART, which was well-tolerated, and had main-
tained a good viral immunological response (CD4> 500/
mmc and undetectable viremia), despite low levels of
fosamprenavir concentration. The more severe toxicities
correlated to sorafenib assumption were grade II hand-
foot skin reaction which required a dose reduction.Discussion
HCC is the fifth most common cancer in the world and
the third most common cause of cancer death. The main
risk factors for developing HCC are the presence of cir-
rhosis and co-infection with HBV and HCV [10].
HIV co-infection worsens the course of viral hepatitis
causing faster progression of fibrosis and earlier develop-
ment of cirrhosis. On the other hand, the introduction of
HAART has increased longevity. Consequently, theFigure 2 Abdomen TC scan: follow up during sorafenib
treatment. Right subdiaphragmatic fluid collection with no
appearance of the solid nodular lesion (same anatomic level of
Figure 1).
Table 1 Summary of CD4 cell count and HIV-RNA values
CD4 cell/mmc (%) HIV-RNA (cp/mL) Notes
Mar 2006; May 2006 574 (15.5) <50 Stop HAART; Start Peg-IFN+ RIBA
Sep 2006 357 (18.8) 12596 Stop Peg-IFN+ RIBA
Oct 2006 - Sep 2007 >350 ≥30000≤ 50000 HCC diagnosis and hepatectomy
Jun 2007 277 (13.2) 85462 Restart HAART
Jan 2008 506 (21.1) <50
Apr 2008 384 (23.6) <50 HCC relapse
Dec 2008 526 (23.7) <50 Start sorafenib
Jan 2009 - Apr 2011 >500 <50
HAART: highly active antiretroviral treatment; Peg-IFN: pegylated- interferon; RIBA: ribavirin; HCC: hepatocarcinoma.
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HCC, are more frequently reported [11].
According to current guidelines, treatment of HCC is
the same for both patients with and without HIV infec-
tion, although the outcome is worse for HIV-positive
patients than their HIV-negative counterparts [11]. Until
2007, chemotherapy had not shown survival benefits for
these patients because the HCC is generally a chemore-
sistant tumor [12]. Sorafenib, a new biological drug re-
cently approved in the EU and USA, has substantially
changed the treatment and natural course of advanced
unresectable HCC. The introduction of this drug has
offered a therapeutic opportunity to patients for whom
no effective treatment was previously available. Sorafenib
is a tyrosine kinase inhibitor directed against several tar-
gets (including vascular-endothelial growth factor
VEGFR2, platelet-derived growth factor (PDGFR)-b and
Raf kinase) that has demonstrated the ability to inhibit
tumor proliferation and angiogenesis in vitro. Two ran-
domized, double-blind, placebo-controlled, multicentre,
phase III trials (the SHARP trial and the Asia-Pacific
trial) have proved that monotherapy with oral sorafenib
prolonged median overall survival and delayed the me-
dian time to progression in patients with advanced HCC
[13].
Three cases of HIV-positive patients treated with sora-
fenib have been described in literature: two patients co-
infected with HBV [6,8] and one patient co-infected with
HCV [7]. Our case is the second report describing the
use of sorafenib for HCC in an HIV-HCV co-infected pa-
tient. Our patient’s survival after administration of sora-
fenib was remarkably prolonged compared with the
overall median survival observed in two recent placebo-
controlled trials (20 months vs. 10,7 months [4] and 6,5
[5]), with no grade 3–4 toxicity. Since objective
responses for HCC patients treated with sorafenib are
very rare, this fuels the hypothesis of a possible synergis-
tic effect of sorafenib with HAART. In particular, ritona-
vir, a protease inhibitor, can inhibit both in vivo and
in vitro the PI3/AKT/mTOR pathway and that couldprovide a molecular biology rationale for explaining, at
least in part, the observed objective response. As previ-
ously described [7], a 50% dose reduction of sorafenib to
200 mg twice daily was scheduled for safety reasons. Me-
tabolism of sorafenib occurs primarily in the liver,
mediated via cytochrome P450 (CYP) 3A4, and concomi-
tant administration with CYP3A4 inducers or inhibitors
may modify sorafenib concentrations [13]. Emtricitabine
and tenofovir have no interactions with P450 (CYP) 3A4
enzyme , but fosemprenavir (FPV) and ritonavir (RTV)
are both P450 CYP3A4 inhibitors and since sorafenib is
metabolized through P450 CYP3A4 that could result in
an increase of the active dose of sorafenib explaining the
favorable outcome for the patient. Consistent with the
limited literature data, a good immune-virological re-
sponse to HAART was maintained throughout the sora-
fenib therapy, despite low levels of fosamprenavir
concentration. Different from the other two cases, at
month 20 of treatment with sorafenib, our patient
showed an increase in alpha-fetoprotein values. The oc-
currence of portal vein thrombosis and new lesions
clearly identify HCC disease progression.
In conclusion, sorafenib may represent a good thera-
peutic option also for the treatment of HIV-HCV co-
infected patients with advanced HCC who are not candi-
dates for surgery or palliative care. However, longitudinal
clinical trials are required in order to confirm both effi-
cacy and safety of sorafenib in co-administration with
antiretroviral drugs.Competing interests
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